Robert Call
Allergy · Richmond, VANPI 1063521904
Payments from drug & device makers
What this record shows
This record is dominated by other: $1,468,010 of the $1,871,682 with a category attached, or 78.4%. Kaleo, Inc. accounts for 99.6% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2021 at $1,426,190 and has fallen 100.0% since, to $143 in 2024. Among allergy clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $5242.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kaleo, Inc.$1.9M
- Pfizer$3K
- Optinose US, Inc.$803
- Genentech USA, Inc.$641
- AstraZeneca$576
- Grifols USA, LLC$505
- plus $3K from 26 others
Across 2,152 payments — averaging $15,906 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$25M
- Incyte Corporation$1.9M
- Merck$1.7M
- Astrazeneca UK Limited$1.5M
- Sanofi US Services Inc.$919K
- Takeda Pharmaceuticals U.S.A., Inc.$724K
- plus $2.5M from 23 others
What the payments were for
- Speaking & faculty fees$2,3750%
- Food & beverage$6,1890%
- Education$120%
- Ownership interest$395,09721%
- Other$1,468,01078%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kaleo, Inc. | 26 | $1,863,430 |
| Pfizer | 26 | $2,856 |
| Optinose US, Inc. | 44 | $803 |
| Genentech USA, Inc. | 41 | $641 |
| AstraZeneca | 29 | $576 |
| Grifols USA, LLC | 22 | $505 |
| GSK | 36 | $460 |
| Sanofi | 23 | $413 |
| Amgen | 20 | $391 |
| CSL Behring | 16 | $263 |
| Novartis | 14 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $157 |
| Boehringer Ingelheim | 9 | $141 |
| Regeneron Healthcare Solutions, Inc. | 8 | $123 |
| Pharming Healthcare, Inc. | 8 | $115 |
| Pharmacosmos Therapeutics Inc. | 2 | $63 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| Alk-abello, Inc | 3 | $58 |
| Covis Pharma GmbH | 3 | $57 |
| Greer Laboratories, Inc. | 3 | $52 |
| Aimmune Therapeutics, Inc. | 3 | $47 |
| AbbVie | 2 | $31 |
| Blueprint Medicines Corporation | 2 | $29 |
| Genentech, Inc. | 2 | $28 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Mylan Pharmaceuticals Inc. | 1 | $13 |
| Regeneron | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$2,491
- TEZSPIRE$118
- Prolastin-C Liquid$118
- Prolastin-C$118
- Xhance$116
- NUCALA$107
How this compares
$1,871,682 in reported general payments places this provider in the 95th percentile of 26 allergy providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 24 | $170 |
Paid to pharmacies, not to this prescriber.
Other allergy in Richmond
- Lawrence GelberRichmond$1.9M
- William HarkRichmond$945K
- Muhammad RaisRichmond$16K
- Zeeshan KhakwaniRichmond$8K
- Kimberly GeorgeRichmond$2K
- Thomas Platts MillsCharlottesville$35K
- Kelly MaplesNorfolk$26K
- Jaimin PatelHenrico$14K
- Sarah SprietFort Belvoir$9K
- Laura IspasLeesburg$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.